A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02245958

Enrollment

Registered

2014-09-22

Start date

2015-08-31

Completion date

2015-12-31

Last updated

2016-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blepharospasm, Cervical Dystonia

Brief summary

This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.

Interventions

OTHERNo Intervention

No treatment (intervention) was administered.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed primary diagnosis of idiopathic cervical dystonia or blepharospasm for at least 2 years * Treatment with Xeomin® and BOTOX® for at least 2 years each.

Exclusion criteria

* Having a neuromuscular junction transmission disorder or taking any medications that could affect neuromuscular junction transmission * Previous surgical procedure involving bone or muscle for the management of cervical dystonia or blepharospasm.

Design outcomes

Primary

Measure	Time frame
Dose of Botulinum Toxin Used to Treat Cervical Dystonia	4 Years
Dose of Botulinum Toxin Used to Treat Blepharospasm	4 Years

Secondary

Measure	Time frame
Botulinum Toxin Inter-injection Intervals	4 Years
Number of Participants with Adverse Events	4 Years
Annual Botulinum Toxin Dose per Patient	4 Years

Countries

Mexico, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026